In addition, RIPK4 knockdown in diffuse large B-cell lymphoma (DLBCL) cells was shown to impair cell survival (Fig. 3), inhibit tumor growth in xenograft experiments as well as sensitize the cells to chemotherapeutic treatment, probably due to inhibition of RIPK4-induced NF-κB activity [167]. This evidence concerns the gene NFKB1 and neoplasm.